Analysts’ Viewpoint
The global influenza vaccine market is expected to grow at a rapid pace in the next few years. This can be ascribed to surge in prevalence of flu, rise in awareness, increase in geriatric population, and government initiatives to promote vaccination. Surge in number of collaborations between market players and governments to ensure availability of flu vaccines, such as swine flu vaccine, in remote areas is expected accelerate market development.
Introduction of new vaccines and increase in adoption in developing and underdeveloped countries offer significant opportunities to market players. Key players are focusing on research and development of innovative influenza vaccines. However, volatility in prices of raw materials used in the manufacture of vaccines, high cost of flu vaccines, and limited awareness and access in developing countries are expected to hamper market progress.
Influenza vaccine, also known as flu shot, is a crucial tool in preventing and controlling the spread of the influenza virus. The flu virus is highly contagious and could cause severe symptoms such as fever, cough, body ache, and fatigue. Influenza vaccines are available in various forms, including the traditional injected vaccine and nasal spray vaccines. Injected vaccine contains inactivated or weakened strains of the flu virus, while nasal spray vaccine contains live but weakened strains of the virus. Both types of vaccine trigger the body's immune system to produce an immune response, which helps protect against future infections.
Influenza vaccines are recommended for everyone over the age of six months, especially for people who are at high risk of developing serious complications from the flu, such as the elderly, young children, pregnant women, and people with weakened immune systems. However, influenza vaccines may not provide complete protection against the flu, and the level of protection could vary depending on factors such as age, health status, and the match between the vaccine and the circulating flu strains. Despite these limitations, influenza vaccines are the most effective way to prevent and control the spread of the flu virus. Regular vaccination, combined with good hygiene practices, such as frequent hand washing and covering the mouth and nose while coughing or sneezing, could help prevent the spread of flu and reduce the risk of serious complications.
Development of robust healthcare infrastructure and introduction of new flu vaccine products are driving global influenza vaccine market growth. Increase in availability of vaccines and expansion of healthcare systems in developing countries are making it easier for people to access these lifesaving products. For instance, in 2021, several major pharmaceutical companies, such as Pfizer and Moderna, announced the launch of new, highly effective influenza vaccines that offer improved protection against a wider range of flu strains. These new vaccines are expected to bolster market development.
Surge in number of collaborations between market players and governments to ensure the availability of flu vaccines in remote areas is propelling the market. For instance, in 2019, GlaxoSmithKline announced collaboration with the Bill and Melinda Gates Foundation to increase access to flu vaccines in low- and middle-income countries.
In terms of type, the inactivated segment dominated the global influenza vaccine market in 2022. Inactivated influenza vaccine is an important tool in preventing and controlling the spread of the flu virus. These vaccines, which are made from dead strains of the flu virus, are the most commonly used form of flu vaccines and are considered safe and effective. One of the key advantages of inactivated influenza vaccines is high level of safety. Since the virus strains used in these vaccines are dead, these cannot cause a live flu infection. This makes inactivated vaccines an ideal option for people who are at higher risk of serious complications from the flu, such as pregnant women, people with weakened immune systems, and young children.
Rise in demand for flu vaccines and increase in awareness about the severity of influenza are propelling the inactivated segment. In 2021, the World Health Organization (WHO) launched a global public awareness campaign to encourage people to get vaccinated against influenza due to the COVID-19 pandemic.
Based on valency, the quadrivalent segment dominated the global market in 2022. Quadrivalent influenza vaccines offer better protection against the flu virus. One of the key advantages of quadrivalent vaccines is increased effectiveness in preventing the flu. Unlike traditional trivalent vaccines, which protect against three strains of the flu virus, quadrivalent vaccines protect against four strains. These vaccines are able to keep pace with rapidly evolving flu viruses and provide better protection. This is particularly important given the unpredictable nature of the flu virus and rapid rate at which it can evolve and change.
In terms of age group, the adult segment accounted for largest global influenza vaccine market share in 2022. The adult population is much larger than the younger population. According to the World Population Review of 2020, the population of adults aged 18 and above was around 4.6 billion, while the population of children aged 12 to 18 was nearly 1.2 billion. Moreover, the number of influenza vaccines for pediatrics is less than that for adults. For instance, the Pfizer-BioNTech vaccine was the first COVID-19 vaccine approved in the U.S., and it was only approved for people aged 16 and above. Thus, the adult population is more likely to get vaccinated than the younger population.
Based on distribution channel, the hospitals & pharmacies segment dominated the global influenza vaccine market in 2022. This is ascribed to increase in availability of flu shot vaccines, expansion of healthcare infrastructure, rise in demand for flu vaccines, and convenience & accessibility. Hospitals and pharmacies are typically located within reach of the majority of the population, and these offer the convenience of walk-in appointments or scheduled visits. This makes them an ideal place for people to receive flu vaccine, particularly given the growing emphasis on preventative healthcare. Pharmacists are well-positioned to provide advice and guidance about the flu vaccine, as well as to administer the vaccine. As flu vaccination becomes increasingly important for preventing the spread of flu, hospital and pharmacy distribution channels are poised to play a crucial role in ensuring that people have access to the vaccines they need to protect themselves and their communities.
North America is one of the largest markets for influenza vaccines. The market in the region is driven by high incidence of flu and well-established healthcare infrastructure. The Centers for Disease Control and Prevention (CDC) recommends that everyone aged six months and older should receive a flu vaccine each year. Furthermore, increase in awareness about the importance of flu vaccination is propelling the influenza vaccine market in North America.
Asia Pacific is an emerging market for influenza vaccines. The market in the region is driven by growing burden of flu and improving healthcare infrastructure. The number of flu cases has increased in countries, such as India, China, and Australia, in the past few years, leading to rise in influenza vaccine market demand. Rise in awareness about the importance of flu vaccination and increase in availability of vaccines are accelerating market growth in Asia Pacific.
The influenza vaccine market report includes vital information about leading influenza vaccine manufacturers operating in the global market. Key players are adopting strategies such as product launches, divestiture, mergers & acquisitions (M&A), and partnerships to strengthen their position in the market. Pfizer, Inc., Sanofi, GlaxoSmithKline (GSK), AstraZeneca, Merck & Co., Inc., Novartis AG, Roche Holding AG, Seqirus (CSL Limited), Johnson & Johnson and Daiichi Sankyo Company, Limited are the prominent players operating in the market.
Key players in the market has been profiled in the report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.
|
Attribute |
Detail |
|
Size in 2022 |
US$ 4.0 Bn |
|
Forecast (Value) in 2031 |
More than US$ 7.2 Bn |
|
Compound Annual Growth Rate (CAGR) |
7.2% |
|
Forecast Period |
2023–2031 |
|
Historical Data Available for |
2017–2022 |
|
Quantitative Units |
US$ Bn for Value |
|
Market Analysis |
It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, and parent industry overview. |
|
Competition Landscape |
|
|
Format |
Electronic (PDF) + Excel |
|
Market Segmentation |
|
|
Regions Covered |
|
|
Countries Covered |
|
|
Companies Profiled |
|
|
Customization Scope |
Available upon request |
|
Pricing |
Available upon request |
The global market was valued at US$ 4.0 Bn in 2022
It is projected to reach more than US$ 7.2 Bn by 2031
The CAGR is anticipated to be 7.2% from 2023 to 2031
Rise in awareness about influenza, improving healthcare infrastructure, and introduction of new vaccine products
The quadrivalent segment held the largest share in 2022
North America is expected to account for leading share during the forecast period
Pfizer, Inc., Sanofi, GlaxoSmithKline (GSK), AstraZeneca, Merck & Co., Inc., Novartis AG, Roche Holding AG, Seqirus (CSL Limited), Johnson & Johnson, and Daiichi Sankyo Company, Limited
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Influenza Vaccine Market
4. Market Overview
4.1. Introduction
4.1.1. Type Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Influenza Vaccine Market Analysis and Forecast, 2017–2031
5. Key Insights
5.1. Reimbursement Scenario by Region/globally
5.2. Diseases Incidence and prevalence
5.3. Regulatory scenario in key region/Countries
5.4. Covid-19 Impact on Industry
6. Global Influenza Vaccine Market Analysis and Forecast, by Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Type, 2017–2031
6.3.1. Inactivated
6.3.2. Live Attenuated
6.4. Market Attractiveness Analysis, by Type
7. Global Influenza Vaccine Market Analysis and Forecast, by Valency
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Valency, 2017–2031
7.3.1. Quadrivalent
7.3.2. Trivalent
7.4. Market Attractiveness Analysis, by Valency
8. Global Influenza Vaccine Market Analysis and Forecast, by Age Group
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by Age Group, 2017–2031
8.3.1. Pediatric
8.3.2. Adult
8.4. Market Attractiveness Analysis, by Age Group
9. Global Influenza Vaccine Market Analysis and Forecast, by Distribution Channel
9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Market Value Forecast, by Distribution Channel, 2017–2031
9.3.1. Hospitals & Pharmacies
9.3.2. Government & Institutional Supply
9.3.3. Others
9.4. Market Attractiveness Analysis, by Distribution Channel
10. Global Influenza Vaccine Market Analysis and Forecast, by Region
10.1. Key Findings
10.2. Market Value Forecast, by Region
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness Analysis, by Region
11. North America Influenza Vaccine Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Type, 2017–2031
11.2.1. Inactivated
11.2.2. Live Attenuated
11.3. Market Value Forecast, by Valency, 2017–2031
11.3.1. Quadrivalent
11.3.2. Trivalent
11.4. Market Value Forecast, by Age Group, 2017–2031
11.4.1. Pediatric
11.4.2. Adult
11.5. Market Value Forecast, by Distribution Channel, 2017–2031
11.5.1. Hospitals & Pharmacies
11.5.2. Government & Institutional Supply
11.5.3. Others
11.6. Market Value Forecast, by Country, 2017–2031
11.6.1. U.S.
11.6.2. Canada
11.7. Market Attractiveness Analysis
11.7.1. By Type
11.7.2. By Valency
11.7.3. By Age Group
11.7.4. By Distribution Channel
11.7.5. By Country
12. Europe Influenza Vaccine Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Type, 2017–2031
12.2.1. Inactivated
12.2.2. Live Attenuated
12.3. Market Value Forecast, by Valency, 2017–2031
12.3.1. Quadrivalent
12.3.2. Trivalent
12.4. Market Value Forecast, by Age Group, 2017–2031
12.4.1. Pediatric
12.4.2. Adult
12.5. Market Value Forecast, by Distribution Channel, 2017–2031
12.5.1. Hospitals & Pharmacies
12.5.2. Government & Institutional Supply
12.5.3. Others
12.6. Market Value Forecast, by Country/Sub-region, 2017–2031
12.6.1. Germany
12.6.2. U.K.
12.6.3. France
12.6.4. Spain
12.6.5. Italy
12.6.6. Rest of Europe
12.7. Market Attractiveness Analysis
12.7.1. By Type
12.7.2. By Valency
12.7.3. By Age Group
12.7.4. By Distribution Channel
12.7.5. By Country/Sub-region
13. Asia Pacific Influenza Vaccine Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Type, 2017–2031
13.2.1. Inactivated
13.2.2. Live Attenuated
13.3. Market Value Forecast, by Valency, 2017–2031
13.3.1. Quadrivalent
13.3.2. Trivalent
13.4. Market Value Forecast, by Age Group, 2017–2031
13.4.1. Pediatric
13.4.2. Adult
13.5. Market Value Forecast, by Distribution Channel, 2017–2031
13.5.1. Hospitals & Pharmacies
13.5.2. Government & Institutional Supply
13.5.3. Others
13.6. Market Value Forecast, by Country/Sub-region, 2017–2031
13.6.1. China
13.6.2. Japan
13.6.3. India
13.6.4. Australia & New Zealand
13.6.5. Rest of Asia Pacific
13.7. Market Attractiveness Analysis
13.7.1. By Type
13.7.2. By Valency
13.7.3. By Age Group
13.7.4. By Distribution Channel
13.7.5. By Country/Sub-region
14. Latin America Influenza Vaccine Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Type, 2017–2031
14.2.1. Inactivated
14.2.2. Live Attenuated
14.3. Market Value Forecast, by Valency, 2017–2031
14.3.1. Quadrivalent
14.3.2. Trivalent
14.4. Market Value Forecast, by Age Group, 2017–2031
14.4.1. Pediatric
14.4.2. Adult
14.5. Market Value Forecast, by Distribution Channel, 2017–2031
14.5.1. Hospitals & Pharmacies
14.5.2. Government & Institutional Supply
14.5.3. Others
14.6. Market Value Forecast, by Country/Sub-region, 2017–2031
14.6.1. Brazil
14.6.2. Mexico
14.6.3. Rest of Latin America
14.7. Market Attractiveness Analysis
14.7.1. By Type
14.7.2. By Valency
14.7.3. By Age Group
14.7.4. By Distribution Channel
14.7.5. By Country/Sub-region
15. Middle East & Africa Influenza Vaccine Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Type, 2017–2031
15.2.1. Inactivated
15.2.2. Live Attenuated
15.3. Market Value Forecast, by Valency, 2017–2031
15.3.1. Quadrivalent
15.3.2. Trivalent
15.4. Market Value Forecast, by Age Group, 2017–2031
15.4.1. Pediatric
15.4.2. Adult
15.5. Market Value Forecast, by Distribution Channel, 2017–2031
15.5.1. Hospitals & Pharmacies
15.5.2. Government & Institutional Supply
15.5.3. Others
15.6. Market Value Forecast, by Country/Sub-region, 2017–2031
15.6.1. GCC Countries
15.6.2. South Africa
15.6.3. Rest of Middle East & Africa
15.7. Market Attractiveness Analysis
15.7.1. By Type
15.7.2. By Valency
15.7.3. By Age Group
15.7.4. By Distribution Channel
15.7.5. By Country/Sub-region
16. Competition Landscape
16.1. Market Player - Competition Matrix (by tier and size of companies)
16.2. Market Share Analysis, by Company (2022)
16.3. Company Profiles
16.3.1. Pfizer, Inc.
16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.1.2. Type Portfolio
16.3.1.3. Financial Overview
16.3.1.4. SWOT Analysis
16.3.1.5. Strategic Overview
16.3.2. Sanofi
16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.2.2. Type Portfolio
16.3.2.3. Financial Overview
16.3.2.4. SWOT Analysis
16.3.2.5. Strategic Overview
16.3.3. GlaxoSmithKline (GSK)
16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.3.2. Type Portfolio
16.3.3.3. Financial Overview
16.3.3.4. SWOT Analysis
16.3.3.5. Strategic Overview
16.3.4. AstraZeneca
16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.4.2. Type Portfolio
16.3.4.3. Financial Overview
16.3.4.4. SWOT Analysis
16.3.4.5. Strategic Overview
16.3.5. Merck & Co., Inc.
16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.5.2. Type Portfolio
16.3.5.3. Financial Overview
16.3.5.4. SWOT Analysis
16.3.6. Novartis AG
16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.6.2. Type Portfolio
16.3.6.3. Financial Overview
16.3.6.4. SWOT Analysis
16.3.7. Roche Holding AG
16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.7.2. Type Portfolio
16.3.7.3. Financial Overview
16.3.7.4. SWOT Analysis
16.3.8. Seqirus (CSL Limited)
16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.8.2. Type Portfolio
16.3.8.3. Financial Overview
16.3.8.4. SWOT Analysis
16.3.9. Johnson & Johnson
16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.9.2. Type Portfolio
16.3.9.3. Financial Overview
16.3.10. Daiichi Sankyo Company, Limited
16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.10.2. Type Portfolio
16.3.10.3. Financial Overview
16.3.10.4. SWOT Analysis
List of Tables
Table 01: Global Influenza Vaccine Market Value (US$ Mn) Forecast, by Type, 2017–2031
Table 02: Global Influenza Vaccine Market Value (US$ Mn) Forecast, by Age Group, 2017–2031
Table 03: Global Influenza Vaccine Market Value (US$ Mn) Forecast, by Valency, 2017–2031
Table 04: Global Influenza Vaccine Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 05: Global Influenza Vaccine Market Value (US$ Mn) Forecast, by Region, 2017–2031
Table 06: North America Influenza Vaccine Market Value (US$ Mn) Forecast, by Country, 2017–2031
Table 07: North America Influenza Vaccine Market Value (US$ Mn) Forecast, by Type, 2017–2031
Table 08: North America Influenza Vaccine Market Value (US$ Mn) Forecast, by Age Group, 2017–2031
Table 09: North America Influenza Vaccine Market Value (US$ Mn) Forecast, by Valency, 2017–2031
Table 10: North America Influenza Vaccine Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 11: Europe Influenza Vaccine Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 12: Europe Influenza Vaccine Market Value (US$ Mn) Forecast, by Type, 2017–2031
Table 13: Europe Influenza Vaccine Market Value (US$ Mn) Forecast, by Age Group, 2017–2031
Table 14: Europe Influenza Vaccine Market Value (US$ Mn) Forecast, by Valency, 2017–2031
Table 15: Europe Influenza Vaccine Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 16: Asia Pacific Influenza Vaccine Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 17: Asia Pacific Influenza Vaccine Market Value (US$ Mn) Forecast, by Type, 2017–2031
Table 18: Asia Pacific Influenza Vaccine Market Value (US$ Mn) Forecast, by Age Group, 2017–2031
Table 19: Asia Pacific Influenza Vaccine Market Value (US$ Mn) Forecast, by Valency, 2017–2031
Table 20: Asia Pacific Influenza Vaccine Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 21: Latin America Influenza Vaccine Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 22: Latin America Influenza Vaccine Market Value (US$ Mn) Forecast, by Type, 2017–2031
Table 23: Latin America Influenza Vaccine Market Value (US$ Mn) Forecast, by Age Group, 2017–2031
Table 24: Latin America Influenza Vaccine Market Value (US$ Mn) Forecast, by Valency, 2017–2031
Table 25: Latin America Influenza Vaccine Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 26: Middle East & Africa Influenza Vaccine Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 27: Middle East & Africa Influenza Vaccine Market Value (US$ Mn) Forecast, by Type, 2017–2031
Table 28: Middle East & Africa Influenza Vaccine Market Value (US$ Mn) Forecast, by Age Group, 2017–2031
Table 29: Middle East & Africa Influenza Vaccine Market Value (US$ Mn) Forecast, by Valency, 2017–2031
Table 30: Middle East & Africa Influenza Vaccine Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
List of Figures
Figure 01: Global Influenza Vaccine Market Value (US$ Mn) Forecast, 2017–2031
Figure 02: Global Influenza Vaccine Market Value Share, by Type (2022)
Figure 03: Global Influenza Vaccine Market Value Share, by Valency (2022)
Figure 04: Global Influenza Vaccine Market Value Share, by Age Group (2022)
Figure 05: Global Influenza Vaccine Market Value Share, by Distribution Channel (2022)
Figure 06: Global Influenza Vaccine Market Value Share, by Region (2022)
Figure 07: Global Influenza Vaccine Market Value Share Analysis, by Type, 2022 and 2031
Figure 08: Global Influenza Vaccine Market Attractiveness Analysis, by Type, 2023–2031
Figure 09: Global Influenza Vaccine Market Value Share Analysis, by Age Group, 2022 and 2031
Figure 10: Global Influenza Vaccine Market Attractiveness Analysis, by Age Group, 2023–2031
Figure 11: Global Influenza Vaccine Market Value Share Analysis, by Valency, 2022 and 2031
Figure 12: Global Influenza Vaccine Market Attractiveness Analysis, by Valency, 2023–2031
Figure 13: Global Influenza Vaccine Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 14: Global Influenza Vaccine Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Figure 15: Global Influenza Vaccine Market Value Share Analysis, by Region, 2022 and 2031
Figure 16: Global Influenza Vaccine Market Attractiveness Analysis, by Region, 2022-2031
Figure 17: North America Influenza Vaccine Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 18: North America Influenza Vaccine Market Value Share Analysis, by Country, 2022 and 2031
Figure 19: North America Influenza Vaccine Market Attractiveness Analysis, by Country, 2023–2031
Figure 20: North America Influenza Vaccine Market Value Share Analysis, by Type, 2022 and 2031
Figure 21: North America Influenza Vaccine Market Attractiveness Analysis, by Type, 2023–2031
Figure 22: North America Influenza Vaccine Market Value Share Analysis, by Age Group, 2022 and 2031
Figure 23: North America Influenza Vaccine Market Attractiveness Analysis, by Age Group, 2023–2031
Figure 24: North America Influenza Vaccine Market Value Share Analysis, by Valency, 2022 and 2031
Figure 25: North America Influenza Vaccine Market Attractiveness Analysis, by Valency, 2023–2031
Figure 26: North America Influenza Vaccine Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 27: North America Influenza Vaccine Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Figure 28: Europe Influenza Vaccine Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 29: Europe Influenza Vaccine Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 30: Europe Influenza Vaccine Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 31: Europe Influenza Vaccine Market Value Share Analysis, by Type, 2022 and 2031
Figure 32: Europe Influenza Vaccine Market Attractiveness Analysis, by Type, 2023–2031
Figure 33: Europe Influenza Vaccine Market Value Share Analysis, by Age Group, 2022 and 2031
Figure 34: Europe Influenza Vaccine Market Attractiveness Analysis, by Age Group, 2023–2031
Figure 35: Europe Influenza Vaccine Market Value Share Analysis, by Valency, 2022 and 2031
Figure 36: Europe Influenza Vaccine Market Attractiveness Analysis, by Valency, 2023–2031
Figure 37: Europe Influenza Vaccine Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 38: Europe Influenza Vaccine Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Figure 39: Asia Pacific Influenza Vaccine Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 40: Asia Pacific Influenza Vaccine Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 41: Asia Pacific Influenza Vaccine Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 42: Asia Pacific Influenza Vaccine Market Value Share Analysis, by Type, 2022 and 2031
Figure 43: Asia Pacific Influenza Vaccine Market Attractiveness Analysis, by Type, 2023–2031
Figure 44: Asia Pacific Influenza Vaccine Market Value Share Analysis, by Age Group, 2022 and 2031
Figure 45: Asia Pacific Influenza Vaccine Market Attractiveness Analysis, by Age Group, 2023–2031
Figure 46: Asia Pacific Influenza Vaccine Market Value Share Analysis, by Valency, 2022 and 2031
Figure 47: Asia Pacific Influenza Vaccine Market Attractiveness Analysis, by Valency, 2023–2031
Figure 48: Asia Pacific Influenza Vaccine Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 49: Asia Pacific Influenza Vaccine Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Figure 50: Latin America Influenza Vaccine Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 51: Latin America Influenza Vaccine Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 52: Latin America Influenza Vaccine Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 53: Latin America Influenza Vaccine Market Value Share Analysis, by Type, 2022 and 2031
Figure 54: Latin America Influenza Vaccine Market Attractiveness Analysis, by Type, 2023–2031
Figure 55: Latin America Influenza Vaccine Market Value Share Analysis, by Age Group, 2022 and 2031
Figure 56: Latin America Influenza Vaccine Market Attractiveness Analysis, by Age Group, 2023–2031
Figure 57: Latin America Influenza Vaccine Market Value Share Analysis, by Valency, 2022 and 2031
Figure 58: Latin America Influenza Vaccine Market Attractiveness Analysis, by Valency, 2023–2031
Figure 59: Latin America Influenza Vaccine Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 60: Latin America Influenza Vaccine Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Figure 61: Middle East & Africa Influenza Vaccine Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 62: Middle East & Africa Influenza Vaccine Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 63: Middle East & Africa Influenza Vaccine Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 64: Middle East & Africa Influenza Vaccine Market Value Share Analysis, by Type, 2022 and 2031
Figure 65: Middle East & Africa Influenza Vaccine Market Attractiveness Analysis, by Type, 2023–2031
Figure 66: Middle East & Africa Influenza Vaccine Market Value Share Analysis, by Age Group, 2022 and 2031
Figure 67: Middle East & Africa Influenza Vaccine Market Attractiveness Analysis, by Age Group, 2023–2031
Figure 68: Middle East & Africa Influenza Vaccine Market Value Share Analysis, by Valency, 2022 and 2031
Figure 69: Middle East & Africa Influenza Vaccine Market Attractiveness Analysis, by Valency, 2023–2031
Figure 70: Middle East & Africa Influenza Vaccine Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 71: Middle East & Africa Influenza Vaccine Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Figure 72: Global Influenza Vaccine Market Share Analysis, by Company, 2022
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Influenza Vaccine Market
*86 figures and 60 tables includes